SCHEMBL1384150

SCHEMBL1384150

OCCCn1cc2c(CCc3ccccc3)c(-c3ccncc3)c(-c3ccc(F)cc3)nc2n1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 11/20 0.46
ADORA2A P29274 6/20 0.43
ADORA1 P30542 6/20 0.43
ADORA3 P0DMS8 5/20 0.43
MAPK13 O15264 1/20 0.42
GCGR P47871 1/20 0.42
MAPK12 P53778 1/20 0.42
MAPK11 Q15759 1/20 0.42
MAP4K4 O95819 1/20 0.41
MAPK9 P45984 1/20 0.41
CSNK1A1 P48729 1/20 0.41
CSNK1D P48730 1/20 0.41
CDC42BPA Q5VT25 1/20 0.41
AURKB Q96GD4 1/20 0.41
MAP4K5 Q9Y4K4 1/20 0.41
PTGS2 P35354 1/20 0.41
SRC P12931 1/20 0.38
BRAF P15056 1/20 0.38
KDR P35968 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1386755 0.92 MAPK14 (0.43) MAPK14ADORA2AADORA1ADORA3MAPK13
SCHEMBL1385397 0.88 MAPK14 (0.46) MAPK14MAPK13GCGRMAPK12MAPK11
SCHEMBL1386525 0.85 MAPK14 (0.47) MAPK14ADORA2AADORA1ADORA3MAPK13
SCHEMBL2929628 0.84 MAPK14 (0.49) MAPK14ADORA2AADORA1ADORA3MAPK13
SCHEMBL1386704 0.82 PDE10A (0.46)
SCHEMBL1384559 0.81 MAPK14 (0.46) MAPK14ADORA2AADORA1ADORA3MAPK13
SCHEMBL1386294 0.81 MAPK14 (0.37) MAPK14ADORA2AADORA1ADORA3MAPK13
SCHEMBL1387083 0.80 MAP4K4 (0.46) MAPK14ADORA2AADORA1ADORA3MAP4K4
SCHEMBL29332356 0.80 MAPK14 (0.48) MAPK14MAPK13GCGRMAPK12MAPK11
SCHEMBL1386354 0.79 PDE10A (0.39) MAPK14MAPK13MAPK12MAPK11MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
JP-4814783-B2 2011-11-16 JP claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
EP-1611131-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach y Compagnia S.A. (ES) 2006-01-04 EP claimed
WO-2004076450-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach Y Compañia S.A. (ES) 2004-09-10 WO claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 MAPK14 34/4885ADORA2A 3463/4885ADORA1 4004/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885ADORA2A 3970/4885ADORA1 4368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.